European Urology - Surgery is an Essential Part of Salvage Treatment in Refractory Germ Cell Tumors
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 893-894 (November 2006) Article Outline: Cisplatin-refractory germ cell tumours represent an unfavourable subgroup of testis cancer patients with a less than 10% chance of long-term survival [1].
read more
|
European Urology - Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1032-1039 (November 2006) 1. Introduction - Germ cell tumor (GCT) represents a model of solid tumor curable with chemotherapy. Cisplatin-based chemotherapy induces long-term remissions in approximately 80% of patients with advanced GCT as primary treatment, while in only 25–30% of patients at relapse/progression [1], [2].
read more
|
